ULTRASONIC SAFETY AND THERAPY IN OPHTHAMALOGY

眼科超声安全和治疗

• 批准号: 6518514
• 负责人: Ernest Joseph Feleppa
• 金额: $ 39.36万
• 依托单位: RIVERSIDE RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-04-01 至 2005-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6518514
• 关键词: athymic mouse; bioimaging /biomedical imaging; biological models; biomedical equipment development; biomedical equipment safety; computer simulation; diagnosis design /evaluation; diagnosis procedure safety; eye disorder diagnosis; eye neoplasms; eye surgery; glaucoma test; laboratory rabbit; mathematical model; miniature swine; neoplasm /cancer therapy; neoplasm /cancer thermotherapy; nonhuman therapy evaluation; noninvasive diagnosis; retina hemorrhage; ultrasonography; ultrasound biological effect; ultrasound therapy

DESCRIPTION (Verbatim from Applicant's Abstract): This program combines biomedical engineering research at Riverside Research Institute (RRI) with biological and medical investigations at the Weill Medical College (WMC) of Cornell University. Its first objective is to develop noninvasive, focussed ultrasound procedures for treating malignant ocular tumors, which threaten life, and vitreous hemorrhages and membranes, which threaten sight. Its second objective is to support the safe use of diagnostic ultrasound techniques that promise fundamental advances in detecting and combating ocular disease. Both objectives involve comprehensive scientif aboutc investigations of how ultrasonic energy can modify the diverse tissues of the eye. Therapy investigations involve the development of novel ultrasonic beams to thermally necrose large segments of tumors before blood-flow cooling occurs. These investigations explore adaptively controlled beams whose geometry will allow the rapid treatment of entire tumor volumes while avoiding collateral damage. Novel concepts using crossed beams are being developed to mechanically disrupt vitreous hemorrhages and membranes, and to hasten their resorption before they lead to tractional retinal detachments and blindness. Monitoring procedures, using advanced diagnostic ultrasound concepts, are being investigated to monitor, and ultimately control, tumor and vitreous treatments. All procedures are thoroughly tested in animal-model experiments. Safety studies are investigating pulsed-Doppler and color-flow imaging of the eye, with particular attention to therrnal damage in the absorptive, avascular lens. Very-high-frequency systems, which can resolve fine-scale (50-llm) structures are also being examined. This program has performed the first study of ocular effects at these high frequencies (near 50 MHz). Research will now evaluate potential risks when these frequencies are used with ultrasonic contrast agents to evaluate ciliary-body perfusion in glaucoma assays. Safety will be determined using calibrated exposures in in-vivo animal eyes and comprehensive follow-up examinations. Results will be disseminated to support continued safety as new systems evolve.

描述（逐字病来自申请人的摘要）：此程序结合了 河滨研究所（RRI）的生物医学工程研究 威尔医学院（WMC）的生物学和医学调查 康奈尔大学。它的第一个目标是发展无创，集中 用于治疗恶性眼肿瘤的超声操作，威胁 生命，玻璃体出血和膜，威胁到视力。第二 目的是支持安全使用诊断超声技术 承诺在检测和对抗眼疾病方面的基本进展。两个都 目标涉及有关如何调查的全面科学。 超声波能够改变眼睛的多种组织。 治疗研究涉及开发新型超声梁 在血液冷却之前，热坏死大部分肿瘤。 这些调查探索了自适应控制的光束，其几何形状将会 允许在避免抵押品的同时快速处理整个肿瘤量 损害。使用交叉梁的新颖概念正在机械上开发 破坏玻璃体出血和膜，并加快其吸收 在它们导致视网膜脱离和失明之前。监视 使用高级诊断超声概念的过程正在 研究以监测并最终控制，肿瘤和玻璃体处理。 在动物模型实验中对所有程序进行了彻底的测试。 安全研究正在研究脉冲多普勒和颜色流成像 眼睛，特别关注吸收性疾病的胸腔损害 镜片。非常高的频率系统，可以解决高尺度（50-llm） 也正在检查结构。该计划已进行了第一个研究 在这些高频（接近50 MHz）处的眼部效应。现在将研究 当这些频率与超声一起使用时，评估潜在风险 对比剂，以评估青光眼测定法中睫状体灌注。安全 将使用体内动物眼睛中的校准暴露和 全面的后续考试。结果将被传播以支持 随着新系统的发展，继续安全。